The FDA on 23 July 2012 approved Tudorza Pressair (aclidinium bromide) from Forest Pharma for the long-term maintenance treatment of...
Circassia Pharmaceuticals announced that the FDA added new data to the Tudorza Pressair (aclidinium bromide inhalation powder) Prescribing Information that...
Positive Phase IV trial results for Tudorza Pressair in COPD patients with CV disease
AstraZeneca and Actavis Plc announced that they have entered into a definitive agreement under which AstraZeneca will acquire the rights...
Covis Pharma announced positive topline results from the AVANT phase III clinical trial for Duaklir (aclidinium bromide 400µg /formoterol 12µg twice-daily) and Eklira (aclidinium bromide 400µg twice-daily) – known as Tudorza in the U.S. This 24-week study achieved statistically significant and clinically important outcomes for all key endpoint measures of efficacy in adult patients with moderate to severe stable chronic obstructive pulmonary disease (COPD)
Almirall has announced that the European Commission has granted marketing approval to Eklira/Bretaris Genuair(aclidinium 322�g twice daily) in all EU...
AstraZeneca has announced it has entered a strategic collaboration with Circassia Pharmaceuticals plc, a respiratory biopharmaceutical company, for the development...